FITC Annexin V Apoptosis Detection Kit with PI

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5 Apoptosis Detection Kit
Ave. Rating
Submit a Review
Product Citations
publications
FITC_Annexin-V_kit_052318
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
  • FITC_Annexin-V_kit_052318
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640914 100 tests £174
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

BioLegend's FITC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE/Texas Red® channel with a bandpass filter 610/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.
Application

FC - Quality tested

Recommended Usage

Staining Procedure:
1. Wash cells twice with cold BioLegend's Cell Staining Buffer, and then resuspend cells in Annexin V Binding Buffer at a concentration of 0.25-1.0 x 107 cells/mL.
2. Transfer 100 µL of cell suspension in a 5 mL test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of Propidium Iodide Solution.
5. Gently vortex the cells and incubate for 15 min at room temperature (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer to each tube. Analyze by flow cytometry with proper machine settings.

Application Notes

Materials Provided:
0.5 ml of FITC Annexin V
1 ml of Propidium Iodide Solution
50 ml of Annexin V Binding Buffer

Materials Not Included:
Cell Staining Buffer (Cat. No. 420201)

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Ranhanathan P, et al. 2013. J AM Soc Nephrol. PubMed
  2. Yu J, et al. 2014. PloS One. 9:114650. PubMed
  3. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  4. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
Product Citations
  1. Markowicz-Piasecka M, et al. 2020. Apoptosis. 25:426. PubMed
  2. Lyu X, et al. 2019. Oncol Rep. 41:3137. PubMed
  3. Su T, et al. 2021. Metabolites. 11:. PubMed
  4. Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed
  5. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  6. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  7. Li MM, et al. 2018. Int J Infect Dis. 70:72. PubMed
  8. Fang H, et al. 2022. Exp Ther Med. 24:440. PubMed
  9. Chen J, et al. 2021. Antioxidants (Basel). 10:. PubMed
  10. Shimonosono M, et al. 2021. Biomolecules. 11:. PubMed
  11. Wang C, et al. 2021. Clin Transl Med. 11:e522. PubMed
  12. Guo Q, et al. 2018. Front Immunol. 9:1197. PubMed
  13. Soonthornchai W, et al. 2019. Asian Pac J Allergy Immunol. N/A. PubMed
  14. Son Y, et al. 2020. Mol Metab. 39:101005. PubMed
  15. Xie T, et al. 2021. Ann Transl Med. 9:1249. PubMed
  16. Kocak P, et al. 2021. Macromol Biosci. 21:e2000287. PubMed
  17. Li D, et al. 2022. Sci Adv. 8:eabm0478. PubMed
  18. Yuan L, et al. 2015. Endocr Relat Cancer. 22: 577 - 591. PubMed
  19. Belo H, et al. 2015. PLoS One. 10: e0139740. PubMed
  20. Morita K, et al. 2020. Cell. 702:181. PubMed
  21. Yang J, et al. 2021. Oncoimmunology. 1875638:10. PubMed
  22. Neumann CKA, et al. 2020. Mol Metab. 34:136. PubMed
  23. Ali DM, et al. 2019. Cell Death Discov. 5:128. PubMed
  24. Yao J, et al. 2018. Onco Targets Ther. 11:3793. PubMed
  25. Choromanska A, et al. 2020. Biomed Rep. 13:32. PubMed
  26. Mahmoud A, et al. 2016. Int J Toxicol. 35: 429 - 437. PubMed
  27. Liu J, et al. 2015. Biochem Biophys Res Commun. 463: Pags 262-267. PubMed
  28. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  29. Shao M, et al. 2018. Evid Based Complement Alternat Med. 2018:6049498. PubMed
  30. Coelho CC, et al. 2019. Sci Rep. 9:11050. PubMed
  31. Orgaz JL, et al. 2020. Cancer Cell. 37:85. PubMed
  32. Vashist A, et al. 2022. Asian Pac J Cancer Prev. 23:3629. PubMed
  33. Chang T, et al. 2016. Sci Rep. 6:23403. PubMed
  34. Korencak M, et al. 2019. JCI Insight. 4. PubMed
  35. Zhang W, et al. 2021. J Clin Invest. 131:. PubMed
  36. Kang DY, et al. 2022. J Oncol. 2022:6737248. PubMed
  37. Tatsuno K, et al. 2019. Cell Death Dis. 10:578. PubMed
  38. Ouyang J, et al. 2019. J Surg Res. 233:221. PubMed
  39. Xiao Y, et al. 2020. Nucleic Acids Res. 48:11113. PubMed
  40. Shen L, et al. 2021. Cell Death Discov. 7:392. PubMed
  41. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  42. Saboor-Maleki S, et al. 2016. Technol Cancer Res Treat. 10.1177/1533034616650119. PubMed
  43. Xie L, et al. 2020. Front Oncol. 1.354166667. PubMed
  44. Fei X, et al. 2019. Cancer Manag Res. 11:4781. PubMed
  45. Balachandran C, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.06.096. PubMed
  46. Kiss E, et al. 2021. Int J Mol Sci. 22:. PubMed
  47. Wu J, et al. 2020. Immunity. 53:115. PubMed
  48. Sareddy G, et al. 2016. Sci Rep. 6: 24185. PubMed
  49. Virumbrales–Muñ oz M, et al. 2019. Sci Rep. 9:6199. PubMed
  50. Allur Subramaniyan S, et al. 2018. Cell Commun Adhes. 24:19. PubMed
  51. Chen J, et al. 2021. J Oncol. 2021:5572402. PubMed
  52. Cao W, et al. 2016. Nat Commun. 7:11687. PubMed
  53. Finetti F, et al. 2020. Cell Death Differ. 27:310. PubMed
  54. Xing W, et al. 2020. J Recept Signal Transduct Res. 1:. PubMed
  55. Perez E, et al. 2020. J Immunol. 205:2489. PubMed
  56. Callender LA, et al. 2021. Nat Commun. 12:3379. PubMed
  57. Liu R, et al. 2021. Oncol Lett. 21:06. PubMed
  58. Sohrabi Y, et al. 2019. Front Immunol. 9:3155. PubMed
  59. Changizi V, et al. 2021. Iran J Med Sci. 46:291. PubMed
  60. Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed
  61. Blue E, et al. 2015. Diabetes. 64: 2664 - 2675. PubMed
  62. Kongkavitoon P, et al. 2016. PLoS One. 11: 0146696. PubMed
  63. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  64. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  65. Soonthornchai W, et al. 2021. Sci Rep. 11:14186. PubMed
  66. Hu K, et al. 2020. Nat Commun. 2778:11. PubMed
  67. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
  68. Ryva B, et al. 2019. Front Oncol. 9:100. PubMed
  69. Flegkas A, et al. 2019. Medicines (Basel). 6:1. PubMed
  70. Wu A, et al. 2020. Cell Death Dis. 11:40. PubMed
  71. Patil M, et al. 2021. Circ Res. 129:1006. PubMed
  72. Abokyi S, et al. 2021. Int J Mol Sci. 22:. PubMed
  73. Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed
  74. Tailor D, et al. 2020. Br J Cancer. . PubMed
  75. Huang S, et al. 2022. J Cancer. 13:2662. PubMed
  76. Merikhian P, et al. 2022. Mol Oncol. 16:485. PubMed
  77. Zhou Y, et al. 2021. NPJ Regen Med. 6:34. PubMed
  78. Wang YL, et al. 2021. Environ Health Perspect. 129:57003. PubMed
  79. Zhou L, et al. 2021. Front Oncol. 11:668617. PubMed
  80. Dudek M, et al. 2021. Nature. 592:444. PubMed
  81. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  82. Ma H, et al. 2015. Sci Rep. 5: 15121. PubMed
  83. Kan L, et al. 2015. PLoS One. 10: 0144513. PubMed
  84. Viereckl MJ, et al. 2022. Biomolecules. 12:. PubMed
  85. Roupakia E, et al. 2021. Cancers (Basel). 13:. PubMed
  86. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  87. Zhou Q, et al. 2020. J Invest Dermatol. . PubMed
  88. Chou ST, et al. 2020. Chin Med. 0.678472222. PubMed
  89. Weiss R, et al. 2015. Innate Immunity. 21: 813 - 826. PubMed
  90. Yu J, et al. 2014. PLoS One. 9:114650. PubMed
  91. Cho S, et al. 2019. Transl Oncol. 0.820138889. PubMed
  92. Wang JS, et al. 2021. Nat Commun. 12:6271. PubMed
  93. Li XR, et al. 2020. Neoplasma. 67:982. PubMed
  94. Zakharova I, et al. 2022. Front Bioeng Biotechnol. 10:772981. PubMed
  95. Yang Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  96. Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed
  97. Zamani K, et al. 2021. BMC Biotechnol. 21:68. PubMed
  98. Biadglegne F, et al. 2021. Mol Med Rep. 24:. PubMed
  99. Choromanska A, et al. 2020. Pharmaceutics. 12:00. PubMed
  100. Levy G, et al. 2015. PLoS One. 10: 0136070. PubMed
  101. Li C, et al. 2018. Cell Physiol Biochem. 45:366. PubMed
  102. Wang X, et al. 2020. Onco Targets Ther. 13:1691. PubMed
  103. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  104. Wang W, et al. 2020. Cancer Cell Int. 1.06875. PubMed
  105. Lin B, et al. 2020. Mol Med Rep. 21:2171. PubMed
  106. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  107. Lauko A, et al. 2022. Cell Rep. 40:111348. PubMed
  108. Zhong X, et al. 2021. Oncol Lett. 245:21. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 4    Revision Date: 11/01/2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account